245
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)

ORCID Icon, , , , , ORCID Icon, , , ORCID Icon & show all
Pages 1532-1535 | Received 29 Sep 2020, Accepted 30 Jan 2021, Published online: 22 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Maximilian Stahl, Martin S. Tallman & Aaron D. Goldberg. (2021) Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. Leukemia & Lymphoma 62:9, pages 2050-2051.
Read now

Articles from other publishers (2)

Lijie Han, Yilu Li, Jiaying Wu, Jie Peng, Xiaolin Han, Hongmian Zhao, Chen He, Yuanyuan Li, Weimin Wang, Mengmeng Zhang, Yafei Li, Hui Sun, Haixia Cao, Li’na Sang, Zhongxing Jiang & Jifeng Yu. (2022) Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1. International Journal of Hematology 116:6, pages 892-901.
Crossref
Michael J. Hochman & Robert P. Hasserjian. (2022) Survival of the Fittest: Hypomethylating Agent/BCL-2 Inhibitor Combination Versus Intensive Chemotherapy As Frontline Treatment for Acute Myeloid Leukemia. The Hematologist 19:2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.